OBJECTIVES:
I. To conduct a pilot study of omega-3 polyunsaturated fatty acid (PUFA) (omega-3 fatty acid) supplementation in a group of patients with advanced prostate cancer to assess the dose of omega-3 PUFA necessary to achieve an omega-6 to -3 ratio of 1:1 on an individual basis and to assess the clinical impact of omega-3 supplementation on disease progression
OUTLINE:
Patients receive long-term omega-3 polyunsaturated fatty acid (PUFA) supplementation orally (PO).
After completion of study treatment, patients are followed up at 1, 6, and 12 months.
